Feature Type | Standardized |
Nominal ANOVA |
||||
---|---|---|---|---|---|---|
mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.0068 | 0.9 |
mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
mRNA | SCH-79797 | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | 0.0069 | 0.9 |
mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.9 |
mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.0064 | 0.9 |
mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.9 |
mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
mRNA | AZD-2281 | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |